Loading...
Market
PepFlow AI Model to secure major pharma partnership in 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases from pharmaceutical companies, University of Toronto announcements
Story
University of Toronto's PepFlow AI Model Surpasses AlphaFold 2 in Peptide Prediction, Boosting Supercomputing
Jun 29, 2024, 10:01 AM
Researchers at the University of Toronto's Donnelly Centre have developed a new AI model, PepFlow, which surpasses the performance of Google DeepMind's AlphaFold 2 in predicting peptide structures. This breakthrough in AI and supercomputing is expected to accelerate drug discovery and provide deeper insights into disease mechanisms. The development of PepFlow highlights the significant advancements in AI technology, particularly in the field of protein structure prediction, which has been a critical area of study for structural biologists for nearly a century.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
